Welcome to our dedicated page for Telomir Pharms news (Ticker: TELO), a resource for investors and traders seeking the latest updates and insights on Telomir Pharms stock.
Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) is a preclinical-stage biotechnology company whose news flow centers on Telomir-1, its lead small-molecule candidate targeting epigenetic and metabolic drivers of cancer, aging, and age-related disease. Company press releases and corresponding 8‑K filings provide detailed updates on preclinical data, regulatory progress, and corporate developments related to this program.
Investors following TELO news will find frequent reports on oncology studies, including results in triple-negative breast cancer, prostate cancer, pancreatic cancer, and leukemia models. Recent announcements describe Telomir-1’s effects on tumor growth and metastatic spread in TNBC xenografts, reductions in PSA levels and tumor volume in prostate cancer systems, and dose-dependent cytotoxicity in aggressive leukemia cells. Other updates highlight Telomir-1’s impact on DNA methylation of tumor-suppressor genes and its inhibition of iron-dependent histone demethylases.
Another key category of Telomir news involves IND-enabling and safety milestones. The company has reported completion of GLP toxicology and safety pharmacology studies in rat and dog models, noting favorable tolerability and consistent systemic exposure after oral dosing. These items are often disclosed both via press release and in Item 8.01 sections of Form 8‑K, giving additional regulatory context.
Corporate and strategic developments also appear in TELO’s news stream. Examples include the binding Letter of Intent to acquire TELI Pharmaceuticals, Inc. to consolidate worldwide rights to Telomir-1, and Nasdaq communications regarding listing rule compliance for annual shareholder meetings. Together, these updates provide insight into Telomir’s scientific progress, regulatory planning, and corporate positioning as it advances Telomir-1 toward potential clinical evaluation.
Telomir Pharmaceuticals (NASDAQ:TELO) has announced groundbreaking preclinical data showing that its lead compound Telomir-1 effectively inhibits three key histone demethylase enzymes: JMJD3, FBXL10, and FBXL11. These enzymes are crucial regulators of gene expression and are implicated in various diseases.
The study, conducted with Eurofins Discovery, demonstrates Telomir-1's potential to treat multiple conditions through epigenetic modulation, including cancer, autoimmune disorders, neurodegeneration, and metabolic dysfunction. The compound has shown superior performance compared to Paclitaxel and Rapamycin in preclinical cancer models, particularly in reactivating tumor suppressor genes.
The company is advancing Telomir-1's development and plans to finalize its first IND-enabling program, marking a significant step toward clinical trials.
Telomir Pharmaceuticals (NASDAQ:TELO) has announced promising preclinical results for its lead compound Telomir-1 in treating mitochondrial dysfunction. The study, conducted with Smart Assays Biotechnologies, demonstrated that Telomir-1 successfully restored mitochondrial function in Hutchinson-Gilford Progeria Syndrome (HGPS) cells without triggering oxidative stress or cell proliferation.
Key findings show that Telomir-1 increased mitochondrial energy production, reduced reactive oxygen species (ROS), and showed stronger effects in diseased cells compared to healthy controls. The compound's unique profile suggests potential applications in treating neurodegenerative conditions including Parkinson's, Alzheimer's, and ALS, where mitochondrial failure drives disease progression.
The company is currently finalizing IND-enabling work and evaluating potential clinical indications for Telomir-1's development pathway.
Telomir Pharmaceuticals (NASDAQ:TELO) has announced breakthrough preclinical findings for its Telomir-1 drug candidate in treating aggressive prostate cancer. The study demonstrated that Telomir-1 successfully reversed epigenetic gene silencing of STAT1, a crucial tumor suppressor, outperforming both Paclitaxel and Rapamycin in PC3 xenograft models.
The drug showed superior efficacy in a 21-day oral administration trial, fully reversing STAT1 hypermethylation in a dose-dependent manner. Additionally, Telomir-1 reduced hypermethylation of TMS1, another key tumor suppressor, while maintaining a favorable safety profile by not elongating telomeres in cancerous cells.
These findings build upon previous March 2025 results where Telomir-1 reduced tumor volume by approximately 50% and eliminated chemotherapy-induced mortality when combined with Paclitaxel.